News

Data to be presented at the 2019 Genitourinary Cancers Symposium NEW YORK and TOKYO, Feb. 11, 2019 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer is considered metastatic once the cancer has...

Tokyo and Kumamoto, January 22, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and KM Biologics Co., Ltd. (President and Representative Director: Toshiaki Nagasato, “KM Biologics”) announced that the agreement for the distribution by Astellas of human vaccines, etc. and blood plasma products (“the products”), which KM Biologics manufactures and sells...